Carbapenem-Resistant Enterobacteriaceae (CRE) Infection Market Is Expected to Expand at a Healthy Growth Rate by 2032 | Key Players- Recordati, Fedora, Meiji Seika, Taris Bio, Taiho Pharma, and Others

Delveinsight Business Research LLP
DelveInsight’s “Carbapenem-Resistant Enterobacteriaceae (CRE) Infection Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Carbapenem-resistant Enterobacteriaceae Infection Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Carbapenem-Resistant Enterobacteriaceae (CRE) Infection market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Carbapenem-resistant Enterobacteriaceae Infection: An Overview

As per the CDC, CRE stands for Carbapenem-Resistant Enterobacterales. Enterobacterales are an order of germs, specifically bacteria. Many different types of Enterobacterales can develop resistance, including Klebsiella pneumoniae and Escherichia coli (E. coli). These bacteria can cause infections including pneumonia, bloodstream infections, urinary tract infections, wound infections, and meningitis.

In healthcare settings, CRE is transmitted from person to person, often via the hands of healthcare personnel or through contaminated medical equipment. Additionally, sink drains and toilets are increasingly recognized as environmental reservoirs and CRE transmission sources.

Carbapenem-resistant Enterobacteriaceae Infection Market Key Facts

As per the Centers for Disease Prevention and Control (CDC), several antibiotics have been associated with getting CRE, including carbapenems, cephalosporins, fluoroquinolones, and vancomycin. In 2017, CRE caused an estimated 13,100 infections in hospitalized patients, and 1,100 estimated deaths in the United States.

As per a study by Kang et al. (2019), Infection with Multi-drug Resistant Organisms (MDROs) is increasing worldwide, and out of all the MDROs, CRE infections pose a serious threat to public health. In the United States, the reported incidence of CRE infection is 2.93/100,000 people.

According to DelveInsight’s analysis, the incidence of CRE Infection is equal among women and men.

Carbapenem-resistant Enterobacteriaceae Infection Market

Carbapenem-Resistant Enterobacteriaceae (CRE) Infection Market size is anticipated to grow in the coming years owing to the increasing incident population of CRE infection patients in the 7MM, improvement in the diagnosis methodologies, rising awareness of the diseases, incremental healthcare spending across the world, and estimated launch of emerging therapies

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Carbapenem-resistant Enterobacteriaceae Infection market size by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete detail of the Carbapenem-resistant Enterobacteriaceae Infection market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, mechanism of action (MoA), competition with other therapies, brand value, and their impact on the market.

Carbapenem-resistant Enterobacteriaceae Infection Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of diagnosed patient pool and future trends.

Carbapenem-Resistant Enterobacteriaceae (CRE) Infection Epidemiology Segmentation

Total Incident Population of CRE Infection

Type-Specific Incident Population of CRE Infection

Incident Population of CRE Infection by Carbapenemase-Type

Diagnosed and Treatable Population of CRE Infection

Carbapenem-resistant Enterobacteriaceae Infection Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Carbapenem-resistant Enterobacteriaceae Infection market or expected to get launched during the study period. The analysis covers Carbapenem-resistant Enterobacteriaceae Infection market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Carbapenem-resistant Enterobacteriaceae Infection Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Request for Sample PDF Report – https://www.delveinsight.com/sample-request/carbapenem-resistant-enterobacteriaceae-infection-market

Carbapenem-resistant Enterobacteriaceae Infection Therapeutics Analysis

Several approved therapies drive the current therapeutic landscape of CRE infection in the US. The market for CRE infection is estimated to increase in the coming years. The major reason for the upsurge is the launch of the most anticipated therapies, which are considered a threat to the current market. 

Companies across the globe are thoroughly working toward the development of new treatment therapies for CRE infection. The therapies are expected to hit the market in the near future.

Some of the key companies in the Carbapenem-Resistant Enterobacteriaceae (CRE) Infection Market include:

Boston Pharmaceutical

Workhardt

Urovant Sciences

Recordati

Fedora Pharmaceuticals

Meiji Seika Pharma

Taris Bio

Taiho Pharmaceutical

Venatorx Pharmaceuticals

And many others

Carbapenem-Resistant Enterobacteriaceae (CRE) Infection Therapies covered in the report include:

BOS-228

WCK 6777

Nacubactam

Cefepime-Taniborbactam

And several others.

Get More Detailed Insights Into the Emerging Therapies & Key Companies –  https://www.delveinsight.com/sample-request/carbapenem-resistant-enterobacteriaceae-infection-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Carbapenem-resistant Enterobacteriaceae Infection Competitive Intelligence Analysis

4. Carbapenem-resistant Enterobacteriaceae Infection Market Overview at a Glance

5. Carbapenem-resistant Enterobacteriaceae Infection Disease Background and Overview

6. Carbapenem-resistant Enterobacteriaceae Infection Patient Journey

7. Carbapenem-resistant Enterobacteriaceae Infection Epidemiology and Patient Population

8. Carbapenem-resistant Enterobacteriaceae Infection Treatment Algorithm, Current Treatment, and Medical Practices

9. Carbapenem-resistant Enterobacteriaceae Infection Unmet Needs

10. Key Endpoints of Carbapenem-resistant Enterobacteriaceae Infection Treatment

11. Carbapenem-resistant Enterobacteriaceae Infection Marketed Products

12. Carbapenem-resistant Enterobacteriaceae Infection Emerging Therapies

13. Carbapenem-resistant Enterobacteriaceae Infection Seven Major Market Analysis

14. Attribute Analysis

15. Carbapenem-resistant Enterobacteriaceae Infection Market Outlook (7 major markets)

16. Carbapenem-resistant Enterobacteriaceae Infection Access and Reimbursement Overview

17. KOL Views on the Carbapenem-resistant Enterobacteriaceae Infection Market.

18. Carbapenem-resistant Enterobacteriaceae Infection Market Drivers

19. Carbapenem-resistant Enterobacteriaceae Infection Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report – https://www.delveinsight.com/sample-request/carbapenem-resistant-enterobacteriaceae-infection-market

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

 

Other Trending Healthcare Reports by DelveInsight

Functional Electrical Stimulation (FES) Devices Market
“Functional Electrical Stimulation (FES) Devices Market” research report provides comprehensive insights into the Functional Electrical Stimulation (FES) Devices market size, share, trends as well as the key companies and emerging products in the market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Are you a market researcher?

Explore our research partnership options.

Partnerships

Find out what people like and dislike about your competitors, and compare it with your brand performance.

Competitor Analyzer

Generated by Feedzy
%d bloggers like this: